2 results
Approved WMOCompleted
To evaluate the feasibility of 89Zr-bevacizumab-PET imaging as predictive biomarker before and during treatment with everolimus in patients with neuroendocrine tumors.
Approved WMOCompleted
Primary objective(s): To assess the effect of LysaKare® administration on serum potassium concentration in GEP-NET patients eligible for Lutathera® treatmentSecondary objective(s): To confirm the safety profile of LysaKare® infusion in GEP-NET…